Cartesian Therapeutics (RNAC) Preferred Dividend Payments (2015 - 2025)
Cartesian Therapeutics' (RNAC) quarterly Preferred Dividend Payments came in at $2.6 million in Q2 2025, down 37.55% year-on-year from $4.2 million in Q2 2024, and down 37.55% on a QoQ basis from $4.2 million in Q2 2024.
Cartesian Therapeutics (RNAC) Preferred Dividend Payments (2015 - 2025) Analysis & Trends
Cartesian Therapeutics (RNAC) has 4 years of Preferred Dividend Payments data on file, last reported at $2.6 million in Q2 2025.
- On a quarterly basis, Preferred Dividend Payments fell 37.55% year-over-year to $2.6 million in Q2 2025; TTM through Jun 2025 was $6.8 million, a 62.45% increase from a year earlier, with the FY2016 full-year figure at $4.6 million, down 37.75% from the prior year.
- Preferred Dividend Payments for Q2 2025 stood at $2.6 million, down from $4.2 million in the prior quarter.
- Over the last five years, Preferred Dividend Payments for RNAC reached as high as $4.2 million in Q2 2024 and fell as low as $2.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Cartesian Therapeutics | 210.28 Mn | 210.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 2.63 Mn |
| Jun 30, 2024 | 4.21 Mn |
| Jun 30, 2016 | 2.21 Mn |
| Mar 31, 2016 | 2.36 Mn |
| Dec 31, 2015 | 2.38 Mn |
| Sep 30, 2015 | 1.84 Mn |
| Jun 30, 2015 | 1.56 Mn |